Amyotrophic lateral sclerosis

Related records

Broader conditions (10)

• Anterior horn disorder
• Central nervous system disorder
• Disease
• Disease by body system or component
• Human disease
• Motor neuron disorder
• Nervous system disorder
• Neurodegenerative disease
• Neuromuscular disease
• Spinal cord disorder

Narrower conditions (38)

• Adult progressive spinal muscular atrophy, Aran Duchenne type
• Amyotrophic lateral sclerosis 26 with or without frontotemporal dementia
• Amyotrophic lateral sclerosis 27, juvenile
• Amyotrophic lateral sclerosis 28
• Amyotrophic lateral sclerosis type 1
• Amyotrophic lateral sclerosis type 10
• Amyotrophic lateral sclerosis type 11
• Amyotrophic lateral sclerosis type 12
• Amyotrophic lateral sclerosis type 15
• Amyotrophic lateral sclerosis type 16
• Amyotrophic lateral sclerosis type 18
• Amyotrophic lateral sclerosis type 19
• Amyotrophic lateral sclerosis type 2, juvenile
• Amyotrophic lateral sclerosis type 20
• Amyotrophic lateral sclerosis type 21
• Amyotrophic lateral sclerosis type 22
• Amyotrophic lateral sclerosis type 23
• Amyotrophic lateral sclerosis type 3
• Amyotrophic lateral sclerosis type 4
• Amyotrophic lateral sclerosis type 5

Trials (1,009)

• "New Perspectives of Adaptation to NIV in ALS"
• [18F]ACI-19626 PET in TDP-43 Proteinopathies
• [BrainConnexion] - Neurodevice Phase I Trial
• 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
• 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
• A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis
• A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
• A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
• A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
• A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
• A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)
• A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
• A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
• A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
• A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
• A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
• A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
• A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis
• A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS
• A First in Human Study of ORT247 in Healthy Volunteers

Approved drugs (3)

• Edaravone
• Riluzole
• Tofersen

Drugs in development (147)

• Abatacept Phase 1
• Acetylcarnitine Phase 2
• Acetylcysteine zidrimer Phase 1
• Albumin human Phase 2
• Aldesleukin Phase 2
• Amantadine hydrochloride Phase 2
• Ambroxol Phase 2
• Anakinra Phase 2
• ANX-005 Phase 2
• ARGX-119 Phase 2
• Arimoclomol Phase 3
• Arundic acid Phase 2
• Atropine Phase 2
• Atsm copper (II) Phase 2
• Basiliximab Phase 2
• Biotin Phase 2
• Bosutinib Phase 1
• Caffeine Phase 1
• Cannabidiol Phase 3
• Cannabinol Phase 2

Other linked drugs (5)

• Arhalofenate
• Evetifator
• Nerve growth factor
• Psilocybin
• Tofacitinib